Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lukin

Showing results (841-850 of 866) with videos related to

Pageof 87
Sort By:
Science Advances|May 24, 2024
A brain-enriched circular RNA controls excitatory neurotransmission and restricts sensitivity to aversive stimuliSebastian A Giusti, Natalia S Pino, Camila Pannunzio, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 11, 2020
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative ColitisDana Lukin, David Faleck, Ronghui Xu, et al.
Inflammatory Bowel Diseases|May 4, 2019
Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease OutcomesJenna L Koliani-Pace, Siddharth Singh, Michelle Luo, et al.
Inflammatory Bowel Diseases|June 5, 2024
Diagnosis of Inflammatory Bowel Disease-Associated Peripheral Arthritis: A Systematic ReviewKatherine Falloon, Zahra Dossaji, Pooja Mude, et al.
The American Journal of Gastroenterology|November 4, 2018
Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumNeeraj Narula, Farhad Peerani, Joseph Meserve, et al.
Nature Communications|May 21, 2020
Effects of climate and land-use changes on fish catches across lakes at a global scaleYu-Chun Kao, Mark W Rogers, David B Bunnell, et al.
The American Journal of Gastroenterology|June 28, 2018
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumNeeraj Narula, Farhad Peerani, Joseph Meserve, et al.
BMJ Open Gastroenterology|March 31, 2025
Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trialSiddharth Singh, Jasmine D Nguyen, David I Fudman, et al.
Gastroenterology|June 2, 2018
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's DiseaseParambir S Dulai, Brigid S Boland, Siddharth Singh, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 17, 2020
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative ColitisParambir S Dulai, Siddharth Singh, Niels Vande Casteele, et al.
Pageof 87

Showing results (841-850 of 866) with videos related to

Sort By:
Pageof 87
Science Advances|May 24, 2024
A brain-enriched circular RNA controls excitatory neurotransmission and restricts sensitivity to aversive stimuliSebastian A Giusti, Natalia S Pino, Camila Pannunzio, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 11, 2020
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative ColitisDana Lukin, David Faleck, Ronghui Xu, et al.
Inflammatory Bowel Diseases|May 4, 2019
Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease OutcomesJenna L Koliani-Pace, Siddharth Singh, Michelle Luo, et al.
Inflammatory Bowel Diseases|June 5, 2024
Diagnosis of Inflammatory Bowel Disease-Associated Peripheral Arthritis: A Systematic ReviewKatherine Falloon, Zahra Dossaji, Pooja Mude, et al.
The American Journal of Gastroenterology|November 4, 2018
Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumNeeraj Narula, Farhad Peerani, Joseph Meserve, et al.
Nature Communications|May 21, 2020
Effects of climate and land-use changes on fish catches across lakes at a global scaleYu-Chun Kao, Mark W Rogers, David B Bunnell, et al.
The American Journal of Gastroenterology|June 28, 2018
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumNeeraj Narula, Farhad Peerani, Joseph Meserve, et al.
BMJ Open Gastroenterology|March 31, 2025
Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trialSiddharth Singh, Jasmine D Nguyen, David I Fudman, et al.
Gastroenterology|June 2, 2018
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's DiseaseParambir S Dulai, Brigid S Boland, Siddharth Singh, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 17, 2020
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative ColitisParambir S Dulai, Siddharth Singh, Niels Vande Casteele, et al.
Pageof 87